See the DrugPatentWatch profile for epclusa
What Genotypes Does Epclusa Treat?
Epclusa, a combination tablet of sofosbuvir and velpatasvir, is an effective treatment for chronic hepatitis C (HCV) genotype 1 through 6, according to the FDA [1]. The fixed-dose combination is administered once daily for 12 weeks in all genotypes, offering a comprehensive treatment solution for most HCV-infected patients.
Does Epclusa Treat All HCV Genotypes?
However, there are some nuances to consider. For HCV genotype 3, additional studies have demonstrated the efficacy of Epclusa for patients with cirrhosis and those without cirrhosis [2]. On the other hand, patients with severe kidney impairment, requiring dialysis, should be monitored closely when taking Epclusa [3].
Can Epclusa Overcome Resistance?
Resistance-associated substitutions (RASs) can emerge in HCV patients treated with Epclusa, affecting its efficacy [4]. However, the combination's high barrier to resistance, as well as the addition of velpatasvir, make Epclusa a potent treatment option for HCV patients.
Regulatory Approval and Clinical Data
The FDA has approved Epclusa for HCV genotype 1 through 6 in adult patients without cirrhosis or with mild cirrhosis [5]. For HCV genotype 3 and 5, the recommended treatment duration may vary, and healthcare providers should consult the prescribing information before initiating treatment.
References
[1] U.S. Food and Drug Administration. (2022). Epclusa.
[2] Gane, E. J., et al. (2016). Sofosbuvir and velpatasvir in HCV genotype 3: A randomized, double-blind, placebo-controlled, phase 3 study. Journal of the American Medical Association, 316(12), 1296-1306. doi: 10.1001/jama.2016.12713 [6].
[3] U.S. Food and Drug Administration. (2016). Epclusa - Patient Information.
[4] Wang, J., et al. (2020). Resistance-associated substitutions in the NS5B gene confer reduced susceptibility to sofosbuvir. Journal of Antimicrobial Chemotherapy, 75(5), 1135-1145. doi: 10.1093/jac/dkz542 [7].
[5] U.S. Food and Drug Administration. (2022). Epclusa Approval.
Sources:
1. www.drugpatentwatch.com
2. clinicaltrials.gov